New targets for therapeutic attack

Endocrine-Related Cancer

Volumn 4, Issue 3, 1997, Pages 351-355

  Wakeling, A E ^a   Barker, A J ^a   Davies, D H ^a   Brown, D S ^a   Green, L R ^a   Cartlidge, S A ^a   Woodburn, J R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; NEW DRUG; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; ZM 252868; ZM 254530;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; NONHUMAN; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

EID: 0030742593     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0040351     Document Type: Short Survey

References (18)

1. Barker AJ & Davies DH 1992 Therapeutic preparations containing quinazoline derivatives. European Patent EP-520722-A.
2. Buchdunger E, Trinks U, Mett H, Regenass U, Muller M, Meyer T, McGlynn E, Pinna LA, Traxler P & Lydon NB 1994 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proceedings of the National Academy of Sciences of the USA 91 2334-2338.
3. Burke TR Jr 1992 Protein-tyrosine kinase inhibitors. Drugs of the Future 17 119-131.
4. Ennis BW, Lippman ME & Dickson RB 1991 The EGF receptor system as a target for antitumor therapy. Cancer Investigation 9 553-562.
5. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW & Bridges AJ 1994 A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265 1093-1095.
6. Gibbs B & Oliff A 1994 Pharmaceutical research in molecular oncology. Cell 79 193-198.
7. Gullick WJ 1991 Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. British Medical Bulletin 47 87-98.
8. Hanks SK 1991 Eukaryotic protein kinases. Current Opinion in Structural Biology 1 369-383.
9. Koch CA, Anderson D, Moran MF, Ellis C & Pawson T 1991 SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252 668-674.
10. Powis G & Workman P 1994 Signalling targets for the development of cancer drugs. Anti-Cancer Drug Design 9 263-277.
11. Rajkumar T & Gullick WJ 1994 The Type I growth factor receptors in human breast cancer. Breast Cancer Research and Treatment 29 3-9.
12. Sainsbury JRC, Malcolm AJ, Appleton DR, Farndon JR & Harris AL 1985 Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. Journal of Clinical Pathology 38 1225-1228.
13. Schlessinger Y 1993 How receptor tyrosine kinases activate Ras. Trends in Biochemical Sciences 18 273-275.
14. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA & Woodburn J 1996 Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Research and Treatment 38 67-73.
15. Ward WHJ, Cook PN, Slater AM, Davies DH, Holdgate GA & Green LR 1994 Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochemical Pharmacology 48 659-666.
16. Yaish P, Gazit A, Gilon C & Levitzki A 1988 Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242 933-935.
17. Yarden Y & Ullrich A 1988 Growth factor receptor tyrosine kinases. Annual Review of Biochemistry 57 443-478.
18. Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, Levitzki A, Zilberstein A & Mundy GR 1991 The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Research 51 4430-4435.